Reclassification prediction of first-year protocol biopsy on active surveillance of prostate cancer by p2PSA-related parameters: from PRIAS-JAPAN-Reference-Cited by-同舟云学术

Reclassification prediction of first-year protocol biopsy on active surveillance of prostate cancer by p2PSA-related parameters: from PRIAS-JAPAN

Published:2021-07-12 Issue: Volume: Page:
ISSN:1365-7852
Container-title:Prostate Cancer and Prostatic Diseases
language:en
Short-container-title:Prostate Cancer Prostatic Dis

Author:

Kato Takuma^ORCID,Hirama Hiromi,Mitsuzuka Koji,Maruyama Satoru,Sasaki Hiroshi,Saito Toshihiro,Matsumoto Ryuji,Sakamoto Shinichi,Sakai Yasuyuki,Fukuhara Hiroshi,Naya Yukio,Tsukino Hiromasa,Hara Isao,Ogawa Osamu,Hashine Katsuyoshi,Fumimasa Fukuta,Yokomizo Akira,Tohi Yoichiro^ORCID,Kakehi Yoshiyuki,Sugimoto Mikio

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Urology,Oncology

Link

http://www.nature.com/articles/s41391-021-00422-4.pdf

Reference19 articles.

1. Ferlay JEM, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, et al. Global cancer observatory: cancer today. Lyon, France: International Agency for Research on Cancer; 2018.

2. Bokhorst LP, Valdagni R, Rannikko A, Kakehi Y, Pickles T, Bangma CH, et al. A decade of active surveillance in the PRIAS study: an update and evaluation of the criteria used to recommend a switch to active treatment. Eur Urol. 2016;70:954–60.

3. Mitsuzuka K, Narita S, Koie T, Kaiho Y, Tsuchiya N, Yoneyama T, et al. Pathological and biochemical outcomes after radical prostatectomy in men with low-risk prostate cancer meeting the prostate cancer international: active surveillance criteria. BJU Int. 2013;111:914–20.

4. Sugimoto M, Hirama H, Yamaguchi A, Koga H, Hashine K, Ninomiya I, et al. Should inclusion criteria for active surveillance for low-risk prostate cancer be more stringent? From an interim analysis of PRIAS-JAPAN. World J Urol. 2015;33:981–7.

5. Amin A, Scheltema MJ, Shnier R, Blazevski A, Moses D, Cusick T, et al. The magnetic resonance imaging in active surveillance (MRIAS) trial: use of baseline multiparametric magnetic resonance imaging and saturation biopsy to reduce the frequency of surveillance prostate biopsies. J Urol. 2020;203:910–7.

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Outcomes of active surveillance for Japanese patients with prostate cancer (PRIAS‐JAPAN);BJU International;2024-06-17

2. The Impact of Physical Activity on the Outcomes of Active Surveillance in Prostate Cancer Patients: A Scoping Review;Cancers;2024-02-01

3. Baseline prostate health index risk category and risk category changes during active surveillance predict grade reclassification;Urologic Oncology: Seminars and Original Investigations;2023-11

4. Aggressive Prostate Cancer in Patients Treated with Active Surveillance;Cancers;2023-08-25

5. Role of Perilesional Sampling of Patients Undergoing Fusion Prostate Biopsies;Life;2023-08-10